Cell Therapy News/Articles, page-16849

@col69 Yes its definitely high tide for the whole executive company officers, collectively they have been quite reactive and without urgency. Surely they could engage with Surgcentre for a partnership with regards to CHF. Lets be entirely honest Mesoblast has lost a fair amount of bargaining dividend and the market understands the challenges and business friction they have endured over several years. A partnership will also prove advantageous as a credit raise is just around the corner and the 60 million shorts are waiting for this in eager anticipation, but at what discount and dilution? versus offset CR to a partnership deal which like many shareholders would rather see a discount to partner than another discount to shorters, Times up for MSB to start acring commercial and being more assertive in their dealings, again balance between technical and business acumen.